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Introduction {#sec1}
============

Monocytes that originate from hematopoietic stem cells in the bone marrow have been considered the systemic reservoir of myeloid precursors for the renewal of macrophages and dendritic cells (DCs) ([@bib23]). Numerous master regulators, including PU.1, C/EBPα, FLT3, and miR-223, have been reported to participate in monocyte differentiation ([@bib15], [@bib18]). However, somatic mutation or genetic variation of these master regulators in monocytes often causes hyperplasia and blocks cellular differentiation, resulting in the clinical entity acute monocytic leukemia (AMoL) ([@bib37], [@bib40]). As immune effector cells, macrophages are directly derived from monocytes under inflammatory conditions ([@bib19]). In response to different stimuli, macrophages can be induced to differentiate along two main functional pathways: classical (M1) activation induced by interferon-γ or Toll-like receptor (TLR) agonists and alternative (M2) activation induced by Th2 cytokines such as interleukin (IL)-4 or IL-13 ([@bib21]). M1 macrophages produce high levels of pro-inflammatory factors and inducible NO synthase (iNOS), which are critical for eradicating bacterial, viral, and fungal infections. M2 macrophages are characterized by the high expression of markers of alternative activation, such as arginase-1 (Arg-1) and IL-10, which participate in the response to parasitic infection, tissue remodeling, and tumor progression ([@bib47]). At the molecular level, many transcription factors (TFs), such as nuclear factor (NF)-κB, AP-1, and PU.1, participate in TLR-induced M1 activation, whereas STAT3 and C/EBPβ are involved in the polarization of macrophages to the M2 phenotype ([@bib29], [@bib36], [@bib35]). The epigenetic modifiers JMJD3 and HDACs have also been reported to participate in M2 activation ([@bib22]).

Monocytic leukemia zinc-finger protein (MOZ) is a founding member of the MYST family of lysine acetyltransferases, together with Ybf2/Sas3, Sas2, and TIP60 ([@bib43]). MOZ has intrinsic histone acetyltransferase (HAT) activity, increasing the acetylation of H3K14 and H3K9, leading to chromatin remodeling ([@bib4], [@bib6]). MOZ appears to function as a cofactor for AML1 (RUNX1), PU.1, and p53-mediated gene expression ([@bib26], [@bib41], [@bib25]). Recurrent translocations within the MOZ gene are associated with AMoL ([@bib44]). Fusion proteins such as MOZ-TIF2 and MOZ-NCOA3 retain the N-terminal portion of MOZ and show aberrant functionality, which affects histone modification and gene regulation ([@bib9], [@bib11]). In line with the evidence linking MOZ to leukemia, some studies have highlighted the essential role of MOZ in the development and maintenance of hematopoietic stem cells ([@bib25], [@bib38], [@bib42]). Owing to the lack of a mouse model (the MOZ^−/−^ genotype is embryonic lethal), the molecular functions of MOZ involved in monocyte differentiation and macrophage activation are poorly understood.

MicroRNA (miRNAs) are short, endogenous, single-stranded RNA molecules that regulate gene expression at the posttranscriptional level ([@bib2]). Recent studies have shown that a range of miRNAs have critical functions in the regulation of inflammatory responses in macrophages and monocytes ([@bib32], [@bib18]). miR-223 was in the first cadre of miRNAs discovered to be highly expressed in myeloid cells. The expression of miR-223 is regulated by a combination of factors, including PU.1, E2F1, GATA1, C/EBPα, and C/EBPβ ([@bib16], [@bib39], [@bib12], [@bib48]). miR-223 has been proved to play an important role in granulocyte differentiation by targeting E2F1, and deregulated miR-223 is associated with acute myeloid leukemia (AML) progression ([@bib39]). Before IKKα and STAT3 were confirmed as validated targets of miR-223 in recent studies, it was believed that miR-223^−/−^ macrophages have a stronger response to lipopolysaccharide (LPS) stimulation.

Our initial observation of the significantly reduced MOZ expression in patients with AMoL prompted us to investigate the potential effect of MOZ on AMoL pathogenesis. In this study, knockdown of MOZ in THP-1 cells blocked phorbol myristate acetate, a specific activator of Protein Kinase C (PMA)-induced differentiation and conferred apoptotic resistance to chemotherapeutic-drug-induced cell death. Loss of MOZ diminished TLR-induced M1 activation of macrophages. Our results also demonstrate that MOZ is a validated target and transcriptional repressor of miR-223. Thus our study shows that monocyte differentiation and macrophage activation are regulated by the MOZ-miR-223 network, in which MOZ functions as a key regulator of differentiation and polarization, interlinked with miR-223 in a mutual negative feedback loop.

Results {#sec2}
=======

Low Expression of MOZ Is Associated with Poor Prognosis in AML Cases {#sec2.1}
--------------------------------------------------------------------

The pathogenesis of AML involves the abnormal proliferation and blocked differentiation of a clonal population of myeloid stem cells. Various biomarkers for AML have been identified, such as FLT3-ITD, NPM1 mutants, and C/EBPα mutants. Based on previous reports, MOZ has been found to be fused to other moderators (NCOA3, TFII, p300, etc.) in AMoL caused by chromosome translocation ([@bib11], [@bib3], [@bib5]). However, the specific role of MOZ in AML pathogenesis is not well understood. Here, we applied an integrated approach and analyzed multidimensional data from AML cases in the TCGA and GEO databases to investigate the relationship between MOZ and AML. As shown in [Figure 1](#fig1){ref-type="fig"}A, we found low expression of MOZ in FLT3-TKD, FLT3-ITD, and NPM1 mutant groups, as well as high expression in a C/EBPα mutant group. Given that FLT3-TKD and FLT3-ITD mutants were associated with poor outcomes in AML, whereas improved prognosis was noted in C/EBPα mutant patients, our results suggested that low expression of MOZ was associated with aggravated AML progression. In addition, we performed a correlation analysis between MOZ and well-defined AML biomarkers in AML cases in the TCGA cohort. As shown in [Figure 1](#fig1){ref-type="fig"}B, we found that MOZ was inversely associated with various markers. In addition, we compared the MOZ expression among different subgroups of AML based on the French--American--British(FAB) classification system. Interestingly, we found that the expression of MOZ was lowest in the M5 group in TCGA or GEO cohorts, as presented in [Figure 1](#fig1){ref-type="fig"}C. To determine whether the monocyte proportion in leukemia contributed to the observed low expression of MOZ in the M5 group, we compared the log2-transformed expression value of MOZ in different AML cases grouped by the proportion of monocytes. Indeed, as shown in [Figures 1](#fig1){ref-type="fig"}D and 1A, a high percentage of monocytes was associated with low MOZ expression. To exclude the possibility of intrinsic expression differences, we compared the expression of MOZ in monocytes and other lymphocytes. No significant difference was observed between CD14^+^ monocytes and CD14^-^ lymphocytes (derived from peripheral blood mononuclear cells), as shown in [Figure 1](#fig1){ref-type="fig"}D, suggesting that MOZ was not heterogeneously expressed in diverse cell groups, at least in hematopoietic-derived cell subgroups. Furthermore, M5 patients younger than 65 years with low expression of MOZ in the TCGA cohorts with normal karyotypes showed worsened overall survival, whereas GEO cohorts showed the same trend ([Figure 1](#fig1){ref-type="fig"}F). Collectively, integrated analysis of the TCGA and GEO cohorts suggested that low MOZ was strongly associated with poor clinical outcomes in AMoL.Figure 1Low Expression of MOZ Is Associated with Poor Prognosis in TCGA and GEO Cohorts(A) Statistical analysis of MOZ expression in somatic mutant and normal groups in the GEO or TCGA cohorts.(B) Correlation analysis between MOZ and AML-related biomarker expression in the TCGA database using SPSS.(C) MOZ expression in different subgroups of AML based on the FAB classification system.(D) Comparison of MOZ expression in definite groups with differential proportions of monocytes.(E) Isolated CD14^+^ monocytes and eluted lymphocytes from human peripheral blood mononuclear cells s were used for determining the mRNA level of MOZ by quantitative PCR.(F) Survival analysis of MOZ in patients with AML (M5 subtype younger than 65 years) in TCGA (hazard ratio \[HR\] = 4.01) or GEO cohorts (HR = 1.37) was performed using Kaplan-Meier methods. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; NS, not significant.

MOZ Knockdown Aggravates AMoL Progression {#sec2.2}
-----------------------------------------

To validate the correlation between AMoL development and MOZ expression, we examined the MOZ transcription level in peripheral blood samples from patients with AMoL and healthy volunteers. By using unique primers that were designed to abandon the samples containing MOZ fusion fragments caused by chromosome translocation, we found that MOZ expression was significantly reduced in AMoL samples, as presented in [Figure 2](#fig2){ref-type="fig"}A. Compared with the level in purified monocytes from healthy individuals, a lower level of MOZ was observed in THP-1 cells, which are broadly used as a model for monocyte development and pathogenesis in leukemia research ([Figure 2](#fig2){ref-type="fig"}A). As altered MOZ expression was observed in AMoL, we sought to determine the expression of MOZ during normal monocyte differentiation. As shown in [Figures 2](#fig2){ref-type="fig"}B and 2D, sustaining increased MOZ expression was observed during cytokine-induced primary monocyte development. Similar results were obtained in PMA-induced or 1,25(OH)~2~-VitD~3~ (VD3)-induced THP-1 transformation ([Figures 2](#fig2){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A). In addition, MOZ was also upregulated in PMA- and VD3-induced U937, which is another monocytic AML cell line ([Figure S1](#mmc1){ref-type="supplementary-material"}B). These results suggest that there is a causal connection between MOZ expression and monocyte fate. To address this hypothesis, we established a stable transfected THP-1 or U937 cell line expressing short hairpin RNA against MOZ transcripts (designated as shMOZ), and the efficiency of knockdown was confirmed ([Figures 2](#fig2){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}D). In our experiments, we found that the stem cell maker CD34 was up-regulated in shMOZ cells, whereas loss of MOZ reduced CD38 or CD11b expression when compared with control cells ([Figures 2](#fig2){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}C). In addition, MOZ knockdown arrested the cell cycle in THP-1 cells as evidenced by more cells in the G0 phase ([Figure 2](#fig2){ref-type="fig"}G). Similar results were observed in U937/shMOZ cells, which exhibited decreased proliferation activity ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Vimentin and E-cadherin are well-characterized differentiation-related markers ([@bib34], [@bib45]). Here, we found that the level of vimentin, which is down-regulated by induction with PMA, was higher in shMOZ than in control cells, whereas PMA-induced up-regulation of E-cadherin was significantly lower in shMOZ cells. In addition, shMOZ cells exhibited an impaired differentiation progression, based on lower PMA-induced adherence and limited production of reactive oxygen species (ROS) triggered by LPS stimulation compared with that in control cells ([Figures 2](#fig2){ref-type="fig"}I and [S1](#mmc1){ref-type="supplementary-material"}I). Furthermore, the loss of MOZ conferred apoptosis resistance to THP-1 cells or U937 against cisplatin-induced cell death ([Figures 2](#fig2){ref-type="fig"}J, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G, statistical results shown on the right). Besides, Wright-Giemsa staining showed that higher nuclear-cytoplasmic ratio was present in MOZ knockdown cell ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Taken together, these data confirm the critical role of MOZ in monocyte development and show that loss of MOZ blocks normal differentiation and facilitates AMoL pathogenesis.Figure 2Knockdown of MOZ Promotes AMoL Development(A) Sorted monocytes from peripheral blood of patients with AML or healthy individuals (*left*) or immortal THP-1 cells (*right*) were lysed for quantitative PCR (qPCR), using MOZ-specific primers.(B--D) Monocytes from mouse bone marrow or human peripheral blood and THP-1 cells were treated with M-CSF (20 ng/mL), GM-CSF (100 ng/mL), or PMA (10 μg/mL) for the indicated time periods. qPCR was performed to determine MOZ expression, normalized to GAPDH (B and C). Representative western blot (D) of MOZ is shown.(E) The efficiency of MOZ knockdown in THP-1 cells is shown.(F) shMOZ stable-transfected THP-1 cells and control cells were labeled with anti-CD34 or anti-CD38 antibodies conjugated with fluorescein isothiocyanate or phycoerythrin (PE) and analyzed using flow cytometry.(G) THP-1 shMOZ or control cells were cultured for 24 hr, fixed, and permeabilized with ethanol (100%) overnight. Sequentially, the cells were stained with propidium iodide (PI) at the indicated concentration and examined for cell division using fluorescence-activated cell sorting (FACS).(H) THP-1 shMOZ or control cells treated with PMA (10 μg/mL) at the indicated times were analyzed for E-cadherin and vimentin expression by western blot, and GAPDH was used as the internal control.(I) The cellular shape of paired cells treated with PMA for 24 hr was visualized by light microscopy (up). Paired cells pretreated with PMA (10 μg/mL, 12 hr) were stimulated with or without LPS for an additional 12 hr. Then the cells were incubated with DCFH-DA (10 μM) for another 4 hr and subjected to analysis by FACS.(J) Paired cells were treated with cisplatinum at the indicated concentration for 24 hr. Then the cells were stained with annexin-V and PI for FACS analysis.Data represent one of three independent experiments. Data show means ± SEM. \*p \< 0.05; \*\*p \< 0.01; NS, not significant.

Furthermore, we also used specific inhibitor (MOZ-IN-3) targeting against MOZ to evaluate the role of MOZ in U937. As shown in [Figure S2](#mmc1){ref-type="supplementary-material"}B, U937 treated with MOZ-IN-3 for 15 days had higher nuclear-cytoplasmic ratio induced with PMA or VD3 when compared with non-treated cells. Also, enhanced anti-apoptosis activity to chemotherapeutic-drug-induced cell death was observed in U937 treated with MOZ-IN-3 ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). In line with the observation in MOZ knockdown U937, these results confirmed that MOZ activity was critical for monocyte functions.

Dysregulated MOZ Has Strong Connection with Mutated Myeloid-Related Regulators in AML {#sec2.3}
-------------------------------------------------------------------------------------

To uncover the reason why MOZ is expressed at a low level in AML, especially in AMoL, we screened the sequence 3 kb upstream of the proximal TSS (transcription start site) of the human *MOZ* gene for regulatory elements and corresponding factors using various software available online as detailed in [Figure 3](#fig3){ref-type="fig"}A. Subsequently, the predicted TFs with high scores were organized and ranked for GO analysis. As shown in [Figure 3](#fig3){ref-type="fig"}B, the identified TFs were strongly associated with AML pathogenesis. Based on the knowledge of somatic mutation in some master genes contributing to tumorigenesis, we analyzed the mutant frequency of predicted TFs in various cancer cases in the TCGA cohort. As shown in [Figure 3](#fig3){ref-type="fig"}C, we found that most of these factors possess ≥10% mutant rate among the 500 most mutant cases in the TCGA database. Furthermore, gene co-expression analysis performed using cytoscape software (GeneMINIA module) indicated that MOZ expression was strongly connected with these chosen TFs, especially SP1, SPI-1, and EST-1 ([Figure 3](#fig3){ref-type="fig"}D). In addition, the co-expression network comprised by these TFs and the 10 factors with the highest mutation rate in AML indicated that they shared extensive functional properties ([Figure 3](#fig3){ref-type="fig"}E). Thus based on the above bioinformatic analysis, it is reasonable to assume that impaired MOZ expression in AMoL might be attributable to the abnormal activity of AML-related regulators caused by somatic mutation or deregulation mediated by other modulators.Figure 3Bioinformatics Analysis of the MOZ Promoter(A) A 3-kb sequence located upstream of the proximal TSS of the *MOZ* gene was taken for predicating putative transcription factors (TFs) using various software or databases (COMPEL, JASPAR, PROMO 3.0, FANTOM project, and Ensembl), and the threshold was \>0.9 or \>90, according to different software.(B) GO analysis of predicated TFs.(C) The mutant frequency of predicated TFs in AML cases in TCGA cohorts.(D) A co-expression network was constructed between MOZ (KAT6A) and predicated TFs using cytoscape software.(E) The genes with the highest mutant rate in AML cases were used for co-expression analysis with predicated TFs using cytoscape software.

Loss of MOZ Diminishes the M1 Activation of Macrophage {#sec2.4}
------------------------------------------------------

The above results show that MOZ plays an important role in determining monocyte fate (normal differentiation versus AML pathogenesis). As immune effector cells, macrophages are derived directly from monocytes under normal or inflammatory conditions ([@bib46]). To determine whether MOZ takes part in macrophage functions, we measured the expression of MOZ in activated macrophages induced by TLR agonists. As shown in [Figures 4](#fig4){ref-type="fig"}A and 4B, MOZ was clearly up-regulated after ligand stimulation. It is well accepted that TLR ligands (LPS, poly I:C, or PAM3CK4) induce M1 polarization, whereas the cytokines IL-4 and IL-13 polarize cells to the M2 phenotype, initiating the tolerance reaction ([@bib47]). Here, IL-4 induced the down-regulation of MOZ expression but elevated arginase expression in knockdown cells, indicating that the loss of MOZ was favorable for M2 polarization ([Figures 4](#fig4){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A). To further explore the functions of MOZ in macrophages, we generated a puromycin-resistant RAW264.7 cell line that was stably transfected with the expression cassette of a small interfering RNA targeting MOZ transcripts and *pac* gene coding for an enzyme that degrades puromycin ([Figure 4](#fig4){ref-type="fig"}D). MOZ knockdown macrophages (designed as shMOZ) showed lower production of pro-inflammatory factors such as IL-1β, tumor necrosis factor (TNF) α, and IL-6 in the context of LPS stimulation than control cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). Similar results were obtained in bone-marrow-derived macrophages (BMDMs) transfected with siMOZ ([Figure S1](#mmc1){ref-type="supplementary-material"}B). However, the anti-inflammatory factor IL-10, representing the alternative activation (M2) phenotype, was higher in shMOZ cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). An oxidative burst, producing various highly reactive oxygen derivatives that are critical components of the antimicrobial repertoire of macrophages, can be induced by many external stimuli, such as bacteria, fungi, and viruses ([@bib14]). To investigate whether MOZ regulates antimicrobial reactions in macrophages, we first examined the LPS-induced oxidation level using the classical agent dichloro-dihydro-fluorescein diacetate (DCFH-DA) for indicating the amount of ROS. Consistent with reduced *iNOS* expression in shMOZ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C), MOZ knockdown significantly suppressed the production of ROS in macrophages ([Figure 4](#fig4){ref-type="fig"}G). To assess the role of MOZ in macrophage phagocytosis, we constructed GFP-expressing bacteria using a prokaryotic expression system that was added to the culture media of macrophages. As shown in [Figures 4](#fig4){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}C, lower GFP intensity was observed in shMOZ cells, suggesting that the loss of MOZ attenuated the ability of macrophages to undergo phagocytosis. The bactericidal reaction, as a sequence of events occurring in M1 macrophages, is critical for protecting the body from infection ([@bib1]). Here, we found that MOZ knockdown significantly diminished the bactericidal activity of macrophages, consistent with the effects of MOZ on M1 macrophage functional modulation. Taken together, these data demonstrate that MOZ regulates the cellular functions associated with the M1 phenotype.Figure 4Loss of MOZ Diminishes M1 Activation of Macrophages(A--C) Macrophage cell lines (J774.1 and RAW264.7) or primary BMDMs were incubated with or without LPS (100 ng/mL) for different time periods, and MOZ expression was then quantified using qPCR (A). RAW264.7 cells treated with various TLR agonists (PAM3CK4 5 μM, Poly I:C 10 μg/mL) for 6 hr were examined for MOZ expression by qPCR (B). BMDMs were treated with LPS (100 ng/mL) or IL-4 (20 ng/mL) for different time periods and were monitored for MOZ expression by qPCR (C). Genetic deletion of MOZ in RAW264.7 cells (designated as shMOZ) was confirmed for the efficiency of knockdown using qPCR, western blot, or hybridization.(E and F) Pro-inflammatory factor expression was determined by qPCR at the transcription level (E) or by ELISA for protein production (F) in paired cells treated with LPS (100 ng/mL) for the indicated time periods.(G) Pretreated RAW 264.7 shMOZ or control cells treated with LPS (100 ng/mL) for 6 hr were incubated with DCFH-DA (10 μM) for an additional 4 hr and subjected to fluorescence-activated cell sorting. Shown on the right are the statistical results.(H) Raw264.7 shMOZ or shcon cells were co-cultured with GFP-expressing bacteria (GFP bacteria, *E. coli*) for 4 hr, and the GFP intensity was then detected using FACS. Data represent one experiment of three independent trials.(I) shMOZ or control cells were pretreated with LPS (100 ng/mL) for 12 hr, and live *E*. *coli* was sequentially added for another 2 hr. Then the supernatant was collected and diluted at the indicated times and cultured on agar plates for 24 hr at 37°C. The bacterial colonies were counted, and the colony-forming unit of *E*. *coli* from the supernatant was determined. Similar results were obtained from three independent experiments.Data show the mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; NS, not significant.

MOZ Positively Regulates the TLR Signaling Pathway and Histone Modification Events {#sec2.5}
----------------------------------------------------------------------------------

Macrophage priming with LPS initiates multiple signal transduction events, including NF-κB, mitogen-activated protein kinase (MAPK), and PI3K/AKT, which are ultimately converted into cytokine production and M1 polarization ([@bib47]). To investigate whether MOZ affects the signaling events downstream of TLR4/LPS, we assessed the phosphorylation level of AKT, p65, Erk, p38, and JNK in LPS-stimulated macrophages. As shown in [Figure 5](#fig5){ref-type="fig"}A, knockdown of MOZ slightly affected the phosphorylation level of p65, but significantly decreased the phosphorylation of AKT and MAPKs. However, MOZ did not appear to regulate the expression of total protein of Erk, p38, JNK, and AKT, as evidenced by the similar bands observed in shMOZ and control cells ([Figure 5](#fig5){ref-type="fig"}A). In addition, reporter assays provided the same results with regard to the attenuation of AKT and MAPK signals in shMOZ cells, whereas MOZ did not affect the activity of NF-κB or STAT3 ([Figure 5](#fig5){ref-type="fig"}B). Thus these results suggest that MOZ regulates AKT and MAPK activity, which are crucial for M1 polarization.Figure 5MOZ Knockdown Impairs Multi-pathway Activity and Attenuates Epigenetic Modification of Histone H3(A) Stably transfected RAW264.7 cells with short hairpin RNA (shRNA) targeting MOZ mRNA or control shRNA and six-well-plate-cultured BMDMs that were transiently transfected with small interfering RNA (siRNA) against MOZ or scramble siRNA (20 μM) for 48 hr were treated with LPS (100 ng/mL) at the indicated time points. After stimulation, cells were collected and lysed for immunoblotting analysis.(B) *Foxo1-luc*, *NF-κB-luc*, *AP-1-luc,* and *STATs-luc* reporter plasmids were co-transfected with pRL vectors into LPS-pretreated shMOZ or control cells. The luciferase activity was measured and normalized against *Renilla* luciferase activity.(C) The phosphorylation of histone H3 was determined by western blot analysis in shMOZ or control cells (*up*). Co-immunoprecipitation analysis was conducted to detect the acetylation level of H3 in paired cells (*down*).(D) Chromatin immunoprecipitation analysis using anti-phosphorylated/acetylated H3 antibody to pull down DNA fragments from shMOZ or control cells that were amplified for real-time PCR for determining the enrichment of regulatory elements of the *IL1B* and *TNFA* genes.(E) Intracellular IL-1β expression was detected using western blot in paired cells treated with LPS (100 ng/mL) at the indicated time points.Data are pooled from at least three independent experiments. Data show the mean ± SEM. \*\*p \< 0.01; NS, not significant.

Previous research has shown that MOZ can acetylate lysine-9 residues in histone H3, resulting in condensed chromatin transforming into a more relaxed structure that is associated with greater levels of gene transcription ([@bib43]). To determine whether MOZ regulates the histone acetylation involved in M1 polarization, we examined the acetylation level of H3 histone in LPS-stimulated shMOZ or control cells. As shown in [Figure 5](#fig5){ref-type="fig"}C, the level of acetylated and phosphorylated H3 histone was clearly reduced in shMOZ cells. In addition, chromatin immunoprecipitation assays suggested that acetylated histones binding to the enhancer of pro-inflammatory genes including *IL1B* and *TNFA* were significantly reduced in shMOZ cells ([Figure 5](#fig5){ref-type="fig"}D). In line with this finding, decreased IL-1β production was found in shMOZ cells incubated with LPS for different periods of time ([Figure 5](#fig5){ref-type="fig"}E). Thus these results demonstrate that MOZ positively regulates multiple pathways and H3 histone acetylation to promote M1 polarization.

MOZ Is a New and Reliable Target of miR-223 {#sec2.6}
-------------------------------------------

The literature indicates that miR-223 is highly expressed in myeloid cell linages and participates in AML progression ([@bib27]). To investigate the role of miR-223 in AML, we first analyze the expression of miR-223 in AML cases based on TCGA database. Contrary to MOZ, miR-223 expression was expressed in M4/M5 patients or \>20% group ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), and low expression of miR-223 was associated with favorable prognosis ([Figure S3](#mmc1){ref-type="supplementary-material"}C). To detect the expression of miR-223 or its precursor in patients with clinical AML, we designed specific primers to amplify a fragment containing miR-223, as described in [Figure S5](#mmc1){ref-type="supplementary-material"}A. In accordance with previous reports, we found that the precursor or mature miR-223 was more highly expressed in AML samples or THP-1 cells than in healthy samples ([Figures 6](#fig6){ref-type="fig"}A and 6B). Besides, integrated data from TCGA suggested that miR-223 had inverse correlation with MOZ expression ([Figure S3](#mmc1){ref-type="supplementary-material"}D). To confirm this, we examined miR-223 and MOZ expression during monocyte development. As shown in [Figure 6](#fig6){ref-type="fig"}C, miR-223 was decreased, whereas MOZ was up-regulated during PMA-, granulocyte-macrophage colony-stimulating factor (GM-CSF)-, or macrophage colony-stimulating factor (M-CSF)-induced monocyte-to-macrophage differentiation. Furthermore, we established miR-223 overexpression (designated as pre-miR-223) or knockdown (designated as sponge) cell lines ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Overexpression of miR-223 decreased the nuclear-cytoplasmic ratio, whereas knockdown of miR-223 increased the ratio in U937 ([Figure S3](#mmc1){ref-type="supplementary-material"}J). Meanwhile, overexpression of miR-223 resulted in increased growth of U937 in soft agar containing 8 μg/mL cisplatin, whereas less growth colonies were observed after miR-223 knockdown ([Figure S3](#mmc1){ref-type="supplementary-material"}K). Similar results were obtained from the CCK8 assay, which was used for analyzing the cell viability of parental U937 and the transfectants cells treated with chemotherapeutic drugs ([Figures S3](#mmc1){ref-type="supplementary-material"}H and S3I). Also, overexpression of miR-223 in cells led to lower proliferation activity, whereas miR-223 knockdown promoted U937 proliferation ([Figure S3](#mmc1){ref-type="supplementary-material"}L). All together, these results suggest that miR-223 promotes AML progression and inhibits monocyte differentiation.Figure 6miR-223 Down-regulates MOZ Expression(A) Total RNA was extracted from isolated and purified monocytes from AML patients or helthy volunteers following to be reverse transcribed into cDNA by using random primers or stem-loop RT primers. The cDNA was used for determing the expression precursor or mature miR-223 by using qPCR. (B) THP-1 cells or monocytes from healthy volunteers was lysed by Tirzol reagent, and total RNA was reverse transcribed into cDNA. Precursor miR-223 was examined by using qPCR.(C) miR-223 and MOZ expressions were monitored during PMA-, GM-CSF-, or M-CSF-induced monocyte differentiation at the indicated time points by qPCR.(D) Induced human macrophage derived from monocytes (MDMs) were treated with LPS (100 ng/mL) or IL-4 (20 ng/mL) for the indicated time periods, and miR-223 and MOZ expressions were then determined by qPCR.(E) Schematic representation of the MOZ gene and the conserved regulatory elements in the 3′ UTR.(F and G) RAW264.7 cells were transiently transfected with 20 nM miR-223 mimics or control mimics and 20 nM miR-223 inhibitors or control inhibitors. At day 3 after transfection, the cells were collected and analyzed for MOZ expression by qPCR (F) or western blot (G).(H and I) The alignment of miR-223 and its target sites in the 3′ UTR of the human MOZ gene and the introduced mutated nucleotides for the reporter assay are shown (H). A total of 200 ng psiCheck2-hMOZ-3′ UTR-WT or psiCheck2-hMOZ-3′ UTR-mut (hMOZ-3′UTR or hMOZ-3′ UTR-mut) was co-transfected with 200 ng miR-223 overexpression plasmids into HEK293 cells. After 24 hr, *Renilla* luciferase activity was measured and normalized to firefly luciferase activity (I).(J) RAW264.7 cells were transfected with 20 nM siMOZ, miR-223 mimics, or scramble small interfering RNA. At day 3 after transfection, live *E*. *coli* was added to the media for another 4 hr, and the supernatant was then diluted and cultured on Luria broth agar plates at 37°C for 16 hr. The bacterial colonies were enumerated, and the colony-forming unit of *E*. *coli* from supernatants was determined.Data are pooled from at least three independent experiments. Data show the mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; NS, not significant.

In macrophages, miR-223 has been shown to suppress the expression of M1 phenotype and promote transition to the M2 phenotype ([@bib30], [@bib20]). In agreement with previous reports, we found that miR-223 was also markedly reduced during LPS-induced M1 polarization, whereas M2 polarization induced elevated miR-223 ([Figure 6](#fig6){ref-type="fig"}D). Considering the expression pattern of MOZ and miR-223 in AML or stimulated macrophage, we speculated that MOZ may be a potential target of miR-223. To this end, we analyzed the 3′ UTR of MOZ sequence using TargetScan 5.1, and we found that miR-223 was one of the conserved miRNAs targeting MOZ mRNA ([Figure 6](#fig6){ref-type="fig"}E). To validate this finding, we transfected macrophages with either synthesized miR-223 mimics or miR-223 inhibitor mimics and their corresponding scrambled controls for determining the effect on MOZ expression. As shown in [Figures 6](#fig6){ref-type="fig"}F and 6G, we found that miR-223 inhibited MOZ expression, whereas antagonizing miR-223 function by miR-223 inhibitor mimics enhanced MOZ expression. Overexpression of the precursor transcript of miR-223 resulted in reduced MOZ ([Figures S3](#mmc1){ref-type="supplementary-material"}F and [S5](#mmc1){ref-type="supplementary-material"}E). Besides, MOZ expression was up-regulated in U937 transfected with miR-223 sponge ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Reporter gene assays also demonstrated that MOZ was a validated target of miR-223 ([Figures 6](#fig6){ref-type="fig"}H and 6I). To assess whether miR-223 shares functional properties with MOZ in macrophages, BMDM cells were transfected with miR-223 mimics, siMOZ, or scramble RNA and were then examined for bactericidal activity. As shown in [Figure 6](#fig6){ref-type="fig"}J, like siMOZ, miR-223 mimics significantly suppressed bactericidal activity, suggesting that MOZ mediates the effect of miR-223 on M1 polarization.

MOZ Negatively Regulates miR-223 Expression {#sec2.7}
-------------------------------------------

The critical role of PU.1 in regulating miR-223 expression has been well documented ([@bib16]). MOZ has also been reported to be a co-activator of PU.1 or RUNX1, participating in the regulation of some genes ([@bib25], [@bib26]). To examine whether MOZ contributes to the regulation of miR-223 in macrophages, we compared the transcriptional level of precursor or mature miR-223 in shMOZ and control cells. As expected, knockdown of MOZ enhanced the expression of miR-223 ([Figures 7](#fig7){ref-type="fig"}A and 7B and S5B/C/D). To uncover the mechanism underlying the regulation of miR-223 by MOZ, the 5′-flanking genomic region of the proximal promoter of pri-miR-223 was analyzed using JASPAR software (version: JASPAR, 2014 serve). We found a putative RUNX1-binding motif close to the confirmed PU.1-binding element on the conserved *cis*-acting regulatory element of the pri-miR-223 gene, and a set of reporter vectors were generated as shown in [Figure 7](#fig7){ref-type="fig"}C. Relative reporter activity for each reporter vector was examined using a dual luciferase reporter assay in shMOZ or control cells. As shown in [Figure 7](#fig7){ref-type="fig"}D, pri-miR-223^−760^ reporter activity was significantly higher in shMOZ cells, and a mutated putative RUNX1-binding site still exhibited enhanced activity in shMOZ cells. However, when mutation was introduced into the PU.1-binding sites, the pri-miR-223^PU.1−del^ reporter activity was considerably reduced and there was no difference between shMOZ and control cells. Furthermore, to exclude the possibility that MOZ regulates PU.1 expression, which sequentially affects miR-223, we examined the expression of PU.1 and RUNX1 at the transcript level in shMOZ cells. As shown in [Figure 7](#fig7){ref-type="fig"}E, there was no significant alteration of PU.1 or RUNX1 in shMOZ cells. Collectively, these results demonstrate that MOZ suppresses miR-223 expression by regulating the promoter activity of pri-miR-223, and that the PU.1-binding element on the promoter is critical for this regulation. The details of the underlying mechanism remain to be elucidated in future studies.Figure 7MOZ Functions as a Repressor of the miR-223 Gene(A and B) MOZ knockdown up-regulated miR-223 expression. Precursor or mature miR-223 level was analyzed in RAW264.7 shMOZ or control cells (A) and THP-1 shMOZ or control cells (B) by qPCR.(C) Schematic representation of different miR-223 promoter constructs used for reporter assays.(D) Indicated reporter plasmids were co-transfected with pRL into shMOZ or control cells. After 24 hr, the firefly luciferase activity was measured and normalized to the *Renilla* luciferase activity.(E) PU.1 and RUNX1 levels were determined in shMOZ or shcon cells using qPCR.Data are presented as the mean ± SEM from three independent experiments. Similar results were obtained in three independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; NS, not significant.

Discussion {#sec3}
==========

Previous studies have shown that MOZ fusion proteins, including MOZ-TIF2, MOZ-CBP, and MOZ-NCOA3, are associated with myeloid cancer progression ([@bib9], [@bib17], [@bib11]). However, the precise role of MOZ in AML pathogenesis is not well documented. Mutant analysis of the COSMIC database showed that the somatic mutation rate of MOZ is low (0.37% in hematopoietic and lymphoid tissues). Therefore it is unlikely that somatic mutation is attributable to the deregulation of MOZ in AML progression, although we cannot exclude the deregulation of MOZ fusions in partial patients. In addition, integrated analysis of AML in TCGA or GEO cohorts indicated that MOZ expression is the lowest in the M5 subgroup of AML and is associated with poor prognosis. Therefore combined with the observation that MOZ is up-regulated during normal monocyte development, the aberrant expression of MOZ in AML indicates that MOZ expression is strongly related to monocyte fate. A bioinformatic approach to the analysis of the promoter of the *MOZ* gene predicated a list of TFs with high mutation rates in AML pathogenesis, providing valuable insight into how MOZ is deregulated in AML. In our present work, we found that MOZ knockdown blocked PMA-induced monocyte differentiation and conferred apoptotic resistance to chemotherapeutic-agent-induced cell death. Thus our results reveal that loss of MOZ facilitates the neoplastic transformation of monocytes.

Derived from monocytes, macrophages undergo different activation pathways, categorized as the M1 and M2 phenotypes, in response to different external stimuli. Bacteria- or LPS-induced M1 polarization increases iNOS expression and promotes inflammatory responses mediated by up-regulated pro-inflammatory factors, whereas the M2-polarized phenotype induced by IL-4 enforces Arg-1 and IL-10 expression associated with anti-inflammatory reactions ([@bib21]). In this study, polarized M1 macrophages showed increased MOZ expression, whereas MOZ was down-regulated in IL-4-induced M2 macrophages. Knockdown of MOZ markedly attenuated the M1 activation of macrophages, as demonstrated by the reduced pro-inflammatory expression and impaired capability of phagocytosis and bacterial killing in MOZ-silenced macrophages. Together, these data suggest that MOZ plays a role in controlling the plasticity of macrophage polarization. Therefore any deregulation of MOZ could diminish the ability of macrophages to adjust their differentiation state, which is necessary for macrophages to mount a proper response to environmental cues. Conceivably, a failure of proper polarization will lead to pathologic conditions.

Intrinsic multi-faceted pathways, including the PI3K/AKT, MAPK, and NF-κB pathways, play important regulatory roles in macrophage polarization ([@bib33], [@bib24], [@bib31]). Upon stimulation, the receptors convert external signals into an intracellular cascade of reactions that ultimately lead to downstream transcriptional events. AKT1 kinase has been reported to regulate mitochondrial ROS production in macrophages, which induces mitophagy and modulates apoptotic resistance ([@bib28]). In our experiments, we found that the loss of MOZ reduced phospho-AKT in response to LPS stimulation, which could explain the lower level of ROS in MOZ knockdown cells, at least partially. MOZ has been demonstrated as a co-activator for NF-κB in regulating NF-κΒ-dependent promoters, and the physical interaction between p65 and MOZ has been proved *in vitro* ([@bib7]). However, in macrophages, we did not find that MOZ affected the activity of NF-κB in the context of LPS stimulation. The discrepancy between this previous study and ours could be explained by the different cell systems used (macrophage versus tumor cell lines), and the relatively low affinity of MOZ for p65 exhibited in earlier studies does not definitively show that this functional complex exists, especially in immune cells. MAPKs have at least three distinct signaling modules, including Erk, JNK, and p38 kinases that can phosphorylate the TFs c-Jun or c-Fos and induce the activation of c-Jun/c-Fos (AP-1) to shape M1 macrophage polarization ([@bib31]). In our work, the impaired activity of Erk and JNK kinases, as well as the attenuated AP-1 activity, in MOZ knockdown cells suggested that MOZ could regulate the MAPK pathway to control the plasticity of macrophage polarization. However, the underlying mechanism of MOZ-mediated AKT or MAPK pathway regulation remains to be studied in the future.

Epigenetic modification plays a pivotal role in controlling the plasticity of macrophage polarization. The effector molecules involved in epigenetic regulation, including CBP, MOF, HDAC3, and JMJD2, have been proved to be important in regulating macrophage differentiation states ([@bib22]). MOZ has been reported to acetylate histones H3 and H4, resulting in the chromosome configuration transformation that is required for gene transcription. Indeed, we also found that MOZ regulated the phosphorylation and acetylation of H3, which is critical for pro-inflammatory factor expression. Although detailed information about how MOZ regulates pro-inflammatory factor expression (i.e., whether MOZ-mediated signal transduction and epigenetic modification are synergistic or independent for this process) remains to be explored, our data clearly demonstrate that MOZ plays multi-functional roles in macrophage activation.

miR-223, which is specifically expressed in the myeloid compartment, plays a pivotal role in limiting inflammation to prevent collateral damage during infection and in preventing oncogenic myeloid transformation. Many myeloid-related master regulators have been identified as the targets of miR-223, including C/EBPβ, E2F1, IGF1R, IKKα, NFI-A, and STAT3. Some of these targets are responsible for granulopoiesis. For example, E2F1 and NFI-A have been reported to be suppressed by miR-223 at the posttranscriptional level, as well as act as repressor of miR-223 gene during granulocyte differentiation ([@bib13], [@bib39]). Also, IKKα and C/EBPβ as the targets of miR-223 have been identified to be critical for the differentiation of macrophage or DC ([@bib48]). Zhou et al. have reported that the miR-223/C/EBPβ axis is essential for intestine homeostasis mediated by macrophage or DC. In this article, the authors have demonstrated that miR-223 deletion significantly promoted the differentiation and activation of monocyte-derived dendritic cell (MoDC). Of note, decreased Ly6C^+^ monocytes, which differentiate into intestinal CX3CR1^high^ macrophage, and the tendency of increased granulocyte in miR-223-deficient mice suggests that the miR-223/C/EBPβ axis has an important role in deciding the direction of differentiation from bone marrow (BM) granulocyte and monocyte precursors (GMPs) as reported by Zhou et al. Also, in this article, the authors find that the number of bone-marrow-derived inflammatory DCs from miR-223^−/−^ mice induced by GM-CSF and IL-4 *in vitro* is much higher than from wild-type mice, suggesting that miR-223 suppresses monocyte-to-DC development. However, whether miR-223 affects monotype-to-macrophage differentiation is not mentioned by Zhou et al. Another report has shown that miR-223 is decreased during macrophage differentiation, releasing repression of its target IKKα ([@bib30]). In addition, miR-223 has been proved to diminish M1 macrophage polarization by targeting STAT3 ([@bib8]). In line with these reports, our results showed that miR-223 was decreased during monocyte differentiation and M1 polarization. Also, like E2F1, MOZ, as a target of miR-223, was found to be a repressor of miR-223 expression. Our initial work provides a new auto-regulatory loop mediated by MOZ and miR-223 in monocyte development and macrophage activation. As mentioned above, these identified targets of miR-223 have their distinct roles in myeloid cell functions. Although we cannot rule out the possibility of other targets of miR-223 that are involved in miR-223-mediated monocyte differentiation and macrophage activation in our study, the unique role of MOZ in monocyte development provides a reliable evidence for the dysregulated miR223/MOZ blocking the normal development and promoting AML (M4/M5) pathogenesis, at least partially. And whether these targets have cross talking in miR-223-derived differentiation or inflammation remain to be uncovered in future works ([Figure 8](#fig8){ref-type="fig"}).Figure 8Schematic Representation of a Model for the Role of MOZ and miR-223 in Normal Monocyte Differentiation and in AMoLDuring normal monocyte differentiation (top panel), some master factors promote MOZ expression, which represses miR-223 gene transcription through PU.1-binding sites on the promoter. The decreased miR-223 expression further leads to the accumulation of MOZ, which is critical for M1-related gene expression. When the master factors are deregulated by various mechanisms in AMoL (bottom panel), transactivation of MOZ is inhibited, which results in the accumulation of miR-223. The increased miR-223 suppresses MOZ expression through a negative feedback loop, resulting in a block of monocyte differentiation.

A previous report has shown that MOZ regulates miR-223 expression in the context of sulfatide stimulation in hepatocellular carcinoma cells ([@bib10]). In this article, sulfatide has been shown to induce the disassociation of MOZ from the promoter of pre-miR-223 gene and down-regulation of miR-223 expression. However, there is no direct evidence about MOZ attachment on the promoter being essential for miR-223 gene transcription. Whether MOZ regulates miR-223 directly in hepatocellular carcinoma (HCC) by affecting the acetylation of histone or C/EBPα needs to be uncovered in the future. In our study, MOZ suppresses miR-223 expression through conserved PU.1-binding sites in the promoter of miR-223, mechanistically. Although MOZ has been demonstrated to bind with PU.1 to facilitate PU.1-dependent transcription activity *in vitro* ([@bib25]), the lack of further investigation of this process *in vivo* or in other cell systems cannot exclude alternative methods by which MOZ regulates PU.1-mediated transcriptional events. Based on the finding that PU.1 expression is not affected by MOZ, we consider two possible mechanisms for MOZ in regulating miR-223: one is through the inhibitory effect of MOZ on PU.1-mediated gene transcription through physical interaction and the second is by affecting other modulators involved in PU.1-initiated transcription assembly on the miR-223 promoter that are affected by MOZ. Of course, the detailed underlying mechanism for how MOZ regulates miR-223 remains to be elaborated in subsequent work.

Limitations of the Study {#sec3.1}
------------------------

We want to knock out MOZ in U937 or THP-1 using CRISPR-Cas9 system; however, the efficiency of transfection is very low and we do not obtain the positive clones after several rounds of screening. Also, we try to establish AML mouse model using NOD-SCID mice to make our conclusions more convincing. However, the model in which mice were injected with THP-1 or U937 according to the well-documented protocol as reported in other literatures failed. Besides, although we had proved connection between MOZ and miR-223, we could not distinguish which is the initiator (did MOZ down-regulation in AML result in increased miR-223 or did miR-223 up-regulation result in decreased MOZ) in the regulation loop in AML pathogenesis. Another limitation is that we cannot prove how MOZ regulated signaling pathways in macrophage. We do not know whether MOZ-regulated signaling pathways resulted in cytokine expression, or MOZ regulated the cytokine expression, which induces the activation of signaling pathways.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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